Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2003 1
2007 3
2008 2
2009 1
2010 1
2011 5
2012 1
2015 1
2016 2
2017 1
2019 5
2020 4
2021 3
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, Sathasivam S, Young CA. James E, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593746 Free PMC article. Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. ...The trial p …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegene …
Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life.
Lynch K. Lynch K. Am J Manag Care. 2023 Jun;29(7 Suppl):S112-S119. doi: 10.37765/ajmc.2023.89389. Am J Manag Care. 2023. PMID: 37433092 Free article.
Just 3 disease-modifying treatments-edaravone, riluzole, and sodium phenylbutyrate and taurursodiol (PB/TURSO)-are currently FDA approved to slow progression of amyotrophic lateral sclerosis (ALS). A fourth therapy has been recently approved und …
Just 3 disease-modifying treatments-edaravone, riluzole, and sodium phenylbutyrate and taurursodiol (PB/TURSO)-are currently FDA appr …
Drug treatment for spinal muscular atrophy types II and III.
Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Wadman RI, et al. Cochrane Database Syst Rev. 2020 Jan 6;1(1):CD006282. doi: 10.1002/14651858.CD006282.pub5. Cochrane Database Syst Rev. 2020. PMID: 32006461 Free PMC article.
This results in degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type II do not develop the ability to walk without support and have a shortened life expectancy, whereas children with SMA type III develop the ability …
This results in degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type II do not dev …
Phenotype and management of neurologic intronic repeat disorders (NIRDs).
Finsterer J. Finsterer J. Rev Neurol (Paris). 2023 Mar;179(3):173-182. doi: 10.1016/j.neurol.2022.09.004. Epub 2022 Nov 10. Rev Neurol (Paris). 2023. PMID: 36371266 Review.
The most well-known NIRDs are Friedreich ataxia, spinocerebellar ataxia types-10, -31, and -36, CANVAS, C9Orf72 familial amyotrophic lateral sclerosis (fALS), and myotonic dystrophy-2 (MD2). Phenotypically, NIRDs manifest as mono-organ (e.g. spinocerebellar a …
The most well-known NIRDs are Friedreich ataxia, spinocerebellar ataxia types-10, -31, and -36, CANVAS, C9Orf72 familial amyotrophic …
Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis.
Teyssou E, Muratet F, Amador MD, Ferrien M, Lautrette G, Machat S, Boillée S, Larmonier T, Saker S, Leguern E, Cazeneuve C, Marie Y, Guegan J, Gyorgy B, Cintas P, Meininger V, Le Forestier N, Salachas F, Couratier P, Camu W, Seilhean D, Millecamps S. Teyssou E, et al. Neurobiol Aging. 2021 Mar;99:102.e11-102.e20. doi: 10.1016/j.neurobiolaging.2020.10.015. Epub 2020 Oct 23. Neurobiol Aging. 2021. PMID: 33218681
ANXA11 mutations have previously been discovered in amyotrophic lateral sclerosis (ALS) motor neuron disease. To confirm the contribution of ANXA11 mutations to ALS, a large exome data set obtained from 330 French patients, including 150 familial ALS index ca …
ANXA11 mutations have previously been discovered in amyotrophic lateral sclerosis (ALS) motor neuron disease. To confir …
Application and prospects of butylphthalide for the treatment of neurologic diseases.
Chen XQ, Qiu K, Liu H, He Q, Bai JH, Lu W. Chen XQ, et al. Chin Med J (Engl). 2019 Jun 20;132(12):1467-1477. doi: 10.1097/CM9.0000000000000289. Chin Med J (Engl). 2019. PMID: 31205106 Free PMC article. Review.
OBJECTIVE: The 3-N-butylphthalide (NBP) comprises one of the chemical constituents of celery oil. ...DATA SOURCES: Literature was collected from PubMed and Wangfang database until November 2018, using the search terms including "3-N-butylphthalide," "microcirculatio …
OBJECTIVE: The 3-N-butylphthalide (NBP) comprises one of the chemical constituents of celery oil. ...DATA SOURCES: Literature was col …
Clinical features and differential diagnosis of flail arm syndrome.
Hübers A, Hildebrandt V, Petri S, Kollewe K, Hermann A, Storch A, Hanisch F, Zierz S, Rosenbohm A, Ludolph AC, Dorst J. Hübers A, et al. J Neurol. 2016 Feb;263(2):390-395. doi: 10.1007/s00415-015-7993-z. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705123
The aim of this study was to investigate typical clinical features of FAS with special regard to initial symptoms and differences to classical Charcot type amyotrophic lateral sclerosis (ALS). We retrospectively evaluated the clinical features of 42 FA …
The aim of this study was to investigate typical clinical features of FAS with special regard to initial symptoms and differences to classic …
Drug treatment for spinal muscular atrophy type I.
Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Wadman RI, et al. Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD006281. doi: 10.1002/14651858.CD006281.pub5. Cochrane Database Syst Rev. 2019. PMID: 31825542 Free PMC article.
OBJECTIVES: To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy (SMA) type I. ...It is uncertain whether riluzole has any effect in patients with SMA type I, based on the limited available ev …
OBJECTIVES: To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy ( …
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
Young CA, Ellis C, Johnson J, Sathasivam S, Pih N. Young CA, et al. Cochrane Database Syst Rev. 2011 May 11;(5):CD006981. doi: 10.1002/14651858.CD006981.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2022 May 20;5:CD006981. doi: 10.1002/14651858.CD006981.pub3. PMID: 21563158 Updated. Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis, is a progressive, neurodegenerative condition which may cause dysphagia, as well as limb weakness, dysarthria, emotional lability and respiratory failure. ...SEARCH STRATEGY: …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis, is a progressive, neurodegenerativ …
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.
Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Höglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, Wszolek ZK; Reisensburg Working Group for Tauopathies With Parkinsonism. Ludolph AC, et al. Eur J Neurol. 2009 Mar;16(3):297-309. doi: 10.1111/j.1468-1331.2008.02513.x. Eur J Neurol. 2009. PMID: 19364361 Free PMC article. Review.
These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked …
These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic …
29 results